Bile acid diarrhoea (bile acid malabsorption)
BAD · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Excess colonic bile acids drive secretory, watery diarrhoea, often urgent and post-prandial. Type 1 (ileal disease/resection), type 2 (idiopathic, overlaps IBS-D) and type 3 (post-cholecystectomy, coeliac) are recognised.
Red flags
- Weight loss, rectal bleeding or anaemia (investigate for IBD/cancer)
- Features of terminal ileal Crohn's
- Fat-soluble vitamin deficiency on long-term sequestrant
- Failure to respond to adequate sequestrant trial
Assessment
Differential diagnosis
- IBS with diarrhoea
- Microscopic colitis
- Crohn's disease (terminal ileum)
- Pancreatic exocrine insufficiency
- Coeliac disease
- Post-cholecystectomy diarrhoea
Investigations
- SeHCAT retention scan (7-day retention <15% diagnostic; <5% severe)
- Serum 7α-hydroxy-4-cholesten-3-one (C4) — elevated
- Fasting serum FGF19 (low)
- Colonoscopy with biopsies if organic features (exclude microscopic colitis/IBD)
- Coeliac serology, faecal elastase to exclude mimics
Management
- Suspect in chronic watery diarrhoea, especially urgency, nocturnal/post-prandial, or post-cholecystectomy/ileal disease
- Exclude mimics: coeliac serology, calprotectin, faecal elastase
- Confirm with SeHCAT (or C4/FGF19 where SeHCAT unavailable)
- Where testing is unavailable, a therapeutic trial of a bile acid sequestrant is reasonable
- Start a bile acid sequestrant — colestyramine titrated to effect
- Advise taking sequestrant separately from other medications (≥4 h) to avoid binding
- Consider colesevelam if colestyramine poorly tolerated (better palatability)
- Reduce dietary fat to lessen bile acid stimulation
- Monitor fat-soluble vitamin status with long-term high-dose sequestrants
- Identify and treat type 1 cause (Crohn's terminal ileitis) specifically
- Review response and adjust dose; refer to GI if refractory
Drugs & doses
Colestyramine 4 g PO once daily, titrate up to 8–12 g/day in divided doses
Colesevelam 625 mg, 1–3 tablets PO twice daily (better tolerated)
Colestipol 5 g PO once–twice daily (alternative)
Disposition
Outpatient GI management; investigate underlying ileal disease if type 1 suspected.
Complications & pitfalls
- Dehydration and electrolyte loss
- Fat-soluble vitamin (A, D, E, K) deficiency
- Binding and reduced absorption of co-administered drugs
- Constipation from over-treatment
Exam pearls
- A large proportion of 'IBS-D' is actually unrecognised bile acid diarrhoea
- SeHCAT retention <15% at 7 days confirms the diagnosis; lower values predict better sequestrant response
- Separate sequestrant dosing from levothyroxine, warfarin and other drugs by several hours
- Colesevelam is better tolerated than colestyramine and improves adherence
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.